Expression Changes of CX3CL1 and Interleukin-6 Genes During Remission Induction Therapy in Patients with Acute Myeloid Leukemia

Background: Acute myeloid leukemia (AML) syndrome is a hematologic malignancy due to the extensive clonal proliferation of leukemic precursor cells and is rapidly fatal unless treated or in response to chemotherapy. Cytogenetic findings have an important role in the prognosis and categorization of AML. This study aimed to investigate the expression changes in CX3CL1 and Interleukin-6 ( IL-6 ) genes before and after chemo - therapy as remission induction therapy in AML patients. Materials and Methods: In this study, 69 patients (36 males, 33 female) with AML were selected from tertiary med - ical health centers. A quantitative polymerase chain reaction was performed for mRNA expression of CX3CL1 and IL-6 genes before and after induction chemotherapy using the 2-ΔΔCT method. Results: The expression of CX3CL1 and IL-6 were significantly increased after induction chemotherapy. Also, the ΔCt mean of CX3CL1 and IL-6 mRNA was not significant between AML subtype groups. Conclusion: We showed that chemo - therapy significantly increases the expression of CX3CL1 and IL-6 , which can be used as a prognostic factor of AML. [


Introduction
A cute myeloid leukemia (AML), as the most common type of acute leukemia, is an increased proliferation of precursor cells and acclamation of immature blast cells, which can result in the arrest of maturation.The cure rate of AML is dependent on age, which is about 35% in younger than 60 years, and it is about 15% in those older than 60 years [1].However, more than half of cured patients relapse after AML therapeutics, which may be due to the presence of minimal residual disease [2].This residual presence may be due to chemotherapy.High-dose chemotherapy as a treatment for AML patients rapidly targeting dividing cells can lead to the acclamation of maturated proteins, poor efficacy, and high toxicity of this treatment option [3].In recent studies, novel treatment strategies have been suggested based on small molecules and mediators involved in signal transduction pathways and cell cycle regulation in the prognosis of AML [4,5].In this regard, studies are underway to find non-invasive biomarkers that could be used for diagnosis, classification, and treatment progression [6].Also, these potential markers were initial steps for the investigation of new targeted drug development [7,8].CX3CL1 (fractalkine) can act as an adhesion or chemical molecule for T-cells and natural killer cells.Except for CX3CL1 and CXCL12, which are mainly expressed by neurons and astrocytes, most chemokines are not inherently expressed but can be simulated under various conditions of diseases [9].CX3CL1 expression has been reported in many types of hematopoietic and/or nonhematopoietic cells, such as endothelial and epithelial cells, lymphocytes, neurons, microglial cells, and osteoblasts.CX3CL1 is involved in applying leukocytes associated with multiple inflammatory disorders and in the tumorigenic process and anti-tumor properties [10].The role of CX3CL1/CX3CR1 in the pathogenesis of cancer has long been discussed.The dual activity of CX3CL1 as a chemoattractant for leukocytes and the adhesion molecule for tumor cells that express the receptor may provide various results regarding the tumorigenesis process [11].The CX3CL1/CX3CR1 axis is involved in B-cell chronic lymphocytic leukemia expression in the interaction between leukemia cells and the tumor microenvironment [12].Interleukins (ILs) play an important role in the body's natural immune response and enhance the ability of the immune system to inhibit cancer.IL-6 is involved in both innate and acquired immunity [13].The active form of IL-6 is a homodimer with each subunit being a spherical domain with four alpha-helices.The IL-6 receptor comprises a cytokinebinding subunit and a signal transduction subunit, which belong to the type I cytokine receptor family.AML often produces IL-6 and other cytokines such as colonic stimulating factor (CSF; G-CSF, M-CSF, and GM-CSF), tumor necrosis factor (TNF)-α, and IL-1.AML blast cells that produce only IL-6 could not be independent of in vitro colonies, whereas blast cells that express CSF in addition to IL-6 were able to form such colonies [13,14].IL-6 can modify gene transcription through Janus kinase (JAK) and signal transducers and transcriptional activators (STAT) and could inhibit apoptosis in different types of tumor cells.Also, IL-6 has been known as an inflammatory mediator involved in the biology of carcinoma and can serve as both mitogen and survival factors [15].The aim of this study was to investigate the expression changes of CX3CL1 and IL-6 genes as two important factors during remission induction therapy as a possible prognostic factor in AML patients.

Materials and Methods
In this study, 69 patients diagnosed with AML were selected from the hematology-oncology ward of Namazi hospital affiliated to Shiraz University of Medical Sciences (SUMS) as a tertiary medical health center using the census selection method.Diagnosis of AML was considered based on the World Health Organization (WHO) system.All the procedures were approved by the Ethics Committee of SUMS (code: IR.SUMS.REC.1394-01-01-11234).All subjects signed an informed contest at the beginning of the study.Bone marrow sample was evaluated in the case of morphology and cytochemistry, and classified according to the French-American-British (FAB) classification system.Also, 5 ml of venous blood was sampled for evaluating complete blood count, blast percentage, and hemoglobin (HB) levels.All patients received standard chemotherapy, which consisted of daunorubicin and cytarabine, as well as, for AML-M3 patients, arsenic trioxide and alltrans-retinoic acid (ATRA) in two divided doses in addition to standard remission induction chemotherapy strategy as previously described [16][17][18][19][20].

RNA Isolation and cDNA Synthesiss
Before and after chemotherapy, 5 ml of venous blood was sampled and was collected in ethylenediaminetetraacetic acid (EDTA).The peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque density gradient centrifugation.Total RNA was isolated by Trizol (Invitrogen, Carlsbad, CA, USA) using the RNX-Plus solution (CinnaGen, Tehran, Iran) according to the protocol supplied by the manufacturer as previously described [16-18, 21].

Real-Time Polymerase Chain Reaction (RT-PCR)
The relative mRNA expression of CX3CL1 and IL-6 genes were evaluated by the SYBR Premix Ex Taq II (Tli RNaseH Plus) Master Mix (Takara, Japan).Internal control for minor fluctuations was the glyceraldehyde 3-phosphate dehydrogenase gene, and the expressions of CX3CL1 and IL-6 mRNAs were normalized.The RT-PCR method was performed using SYBR Premix Ex TaqTM II (Tli RNaseH Plus, Takara, Japan) and designed specific primers for each gene in an iQ5 thermocycler (BioRad Laboratories, USA) according to the manufacturer's instructions, as previously described [16][17][18].Primer sequences are presented in Table-1.

Statistical Analysis
The differences in the mean expression levels of CX3CL1 and IL-6 before and after chemotherapy were compared using the paired t-test.To determine significant differences in gene expression levels among patients with a different type of AML (FAB subtypes), we used the one-way ANOVA.Furthermore, a Chi-square test was used to analyze the mean expression levels of CX3CL1 and IL-6 and other laboratory data.The results were analyzed by using SPSS software version 15 (IBM Corp., Armonk, NY, USA).The P-value less than 0.05 was considered significant.

Results
Thirty-six men and 33 women with a mean age of more than 40 years old were evaluated.

Discussion
In this study, the expression changes of CX3CL1 and IL-6 were investigated during remission induction therapy in patients with AML to find out the effect of expression changes of these genes on the prognosis of AML.Based on our data, CX3CL1 and IL-6 expression were increased after chemotherapy.Also, our data showed that the CX3CL1 expression at the baseline was related to WBC count, and it had a significant difference between gender.Also, there was a negative correlation between the ΔCt mean of CX3CL1 and the age of patients.On the other hand, the ΔCt mean of CX3CL1 had a considerable difference References between both genders, while this difference was not observed in the ΔCt mean of IL-6.
As the regulators of the immune system, cytokines play a role in immune response and inflammation.Therefore, they are effective in transplant success [22].The CX3CL1 and IL-6 play an important role in regulating the expression of pro-and anti-inflammatory cytokines [9,13] reported similar results.They reported that the expression of IL-6 and its associated genes in acute leukemia was common in AML but rare in ALL [13].However, the roles of IL-6 and CXCL3 in the development and prognosis of AML are unclear.So, it seems the CX3L1 and IL-6 have important roles in response to the treatment of AML.

Conclusion
Based on the results of our study, increased expression of CX3CL1 and IL-6 after induction chemotherapy might indicate a possible role of these two chemokines in AML.So, CX3L1 and IL-6 can be used as markers to repose the induction chemotherapy.Further large-scale studies are needed to confirm the specific role of CX3CL1 and IL-6 in the prognosis of AML.

Table 1 .
Primer Sequence for RT-PCR

Table 4 .
Change in the ΔCt Mean of CX3CL1 and IL-6 Expression According to Clinical and Laboratory Variable of Patients FAB:French-American-British; WBC: White blood cell; HB: Hemoglobin; PLT: Platelets; LDH: Lactate dehydrogenase; CR: Complete remission; NCR: Not complete remission.
Zeng et al. studied the expression of IL-6 and its receptor in 39 patients AML, 23 patients with acute lymphoblastic leukemia (ALL), and seven patients with acute mixed lineage leukemia (AMLL).They showed high levels of IL-6 were expressed in 21% of AML patients and 29% of AMLL patients, whereas in ALL, the expression of IL-6 was almost negligible[29].Also, Sugiyama et al.